As the holiday season officially kicks off and we transition into the excitement of December, we wanted to take a moment to look back and share some of the impact we made together this past month.
Here is a look at some of the highlights from November:
Clinical Practice Guidelines for the Management of Basal Cell Carcinoma in Gorlin Syndrome have officially been published online by the Journal of the American Academy of Dermatology (JAAD). Funded by a grant from Gorlin Syndrome Alliance (GSA), this important body of work represents a significant advancement in care for individuals living with Gorlin syndrome (GS). The volume of basal cell carcinomas that people with Gorlin syndrome have presents a unique problem in the clinic, and medical literature did not previously provide substantive guidance on how to approach care. The Guidelines are designed to help guide the decision making process between patients and healthcare providers.
We encourage you to share these Guidelines with your or your loved one’s healthcare provider:
A LinkedIn message from Julie Breneiser, GSA Director of Pharmaceutical Relations, helped spark conversations with Medicus Pharma about potential expanded access to their non-surgical SKINJECT treatment for BCCs, and led to an interview with a journalist from Clinical Leader. While this potential opportunity will unfold slowly, we commit to keeping you informed as details become more clear. For now, we are proud to share one of our successes in making contact with pharmaceutical companies who may not know about Gorlin syndrome, but have a product that could potentially provide relief to our community. We are committed to pursuing better therapies for BCC in Gorlin syndrome at every level.
From the GSAPR Desk: